| Literature DB >> 32844461 |
Paula Bray1, Kayla M D Cornett1, Timothy Estilow2,3, Davide Pareyson4, Riccardo Zuccarino5,6, Mariola Skorupinska7, Menelaos Pipis7, Janet E Sowden8, Steven Scherer3, Mary M Reilly7, Michael E Shy5, David N Herrmann8, Joshua Burns1, Katy J Eichinger8.
Abstract
The CMT-FOM is a 13-item clinical outcome assessment (COA) that measures physical ability in adults with Charcot-Marie-Tooth disease (CMT). Test-retest reliability, internal consistency and convergent validity have been established for the CMT-FOM. This current study sought to establish inter-rater reliability. Following an in-person training of six international clinical evaluators we recruited 10 participants with genetically diagnosed CMT1A, (aged 18-74 years, 6 female). Participants were evaluated using the CMT-FOM over 2 days. Participants were given at least a 3 hour rest between evaluations, and were assessed twice each day. Following the provision of training by master trainers, all 13 items of the CMT-FOM exhibited excellent inter-rater reliability for raw scores (ICC1,1 0.825-0.989) and z-scores (ICC1,1 0.762-0.969). Reliability of the CMT-FOM total score was excellent (ICC1,1 0.983, 95% CI 0.958-0.995). The CMT-FOM is a reliable COA used by clinical evaluators internationally. The next steps are to establish further validation through psychometric evaluation of the CMT-FOM in the Accelerate Clinical Trials in CMT (ACT-CMT) study.Entities:
Keywords: clinical evaluation; clinical outcome assessment; functional measurement; measurement
Year: 2020 PMID: 32844461 PMCID: PMC7520097 DOI: 10.1111/jns.12406
Source DB: PubMed Journal: J Peripher Nerv Syst ISSN: 1085-9489 Impact factor: 3.494